[Chronic myeloproliferative diseases. Current therapeutic standards and new developments].
Chronic myeloproliferative diseases (CMPD) are haematopoetic neoplasias with indolent course and preserved cellular function of the maturing malignant cells. In Philadelphia-positive chronic myeloid leukaemia the discovery of molecular disease mechanisms led to the successful introduction of targeted therapy with imatinib. Ph-negative CMPD are conventionally treated by cytoreduction and low dose ASS in order to minimise the risk of vascular complications. For all CMPD, lifelong surveillance and therapy are necessary.
Krause
S W
SW
Medizinische Klinik 5, Universitätsklinikum Erlangen, Erlangen, Deutschland.
Mackensen
A
A
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000628:therapy; D009196:Myeloproliferative Disorders / Q000175:diagnosis / Q000628:therapy*; D010879:Piperazines / Q000627:therapeutic use; D011087:Polycythemia Vera / Q000628:therapy; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use; D013922:Thrombocytosis / Q000175:diagnosis / Q000628:therapy
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate